CTP-543 matching placebo

DRUG5 trials

Sponsors

Concert Pharmaceuticals

Conditions

Alopecia Areata

Phase 2

Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

CompletedNCT03137381

Concert PharmaceuticalsAlopecia Areata

Start: 2017-08-09End: 2019-07-08Updated: 2022-07-19

Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

CompletedNCT03811912

Concert PharmaceuticalsAlopecia Areata

Start: 2019-03-21End: 2019-11-21Updated: 2022-12-09

Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

CompletedNCT03941548

Concert PharmaceuticalsAlopecia Areata

Start: 2019-05-24End: 2020-04-10Updated: 2023-04-05

Phase 3

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)

CompletedNCT04518995

Concert PharmaceuticalsAlopecia Areata

Start: 2020-11-23End: 2022-04-19Updated: 2023-05-03

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)

CompletedNCT04797650

Concert PharmaceuticalsAlopecia Areata

Start: 2021-06-10End: 2022-06-29Updated: 2023-07-03

Related Papers

Dose optimization of deuruxolitinib in adults with alopecia areata: A phase 2 randomized trial.

2026-09-11

Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial.

2025-11-27

Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1).

2024-07-2337 citations

Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata.

2024-07-061 citations